3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Active not recruiting
12
Recruiting
6
Completed
3
Terminated
1
Suspended
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
2
Tumor-Agnostic
1
Conditions
Breast Neoplasms
2
Neoplasms, Unknown Primary
1
Interventions
pembrolizumab
244
Nivolumab
140
Cisplatin
135
Cyclophosphamide
134
Paclitaxel
113
Carboplatin
108
Gemcitabine
98
Radiotherapy
83
Dexamethasone
83
Docetaxel
77
atezolizumab
68
Ipilimumab
68
Doxorubicin
62
Fluorouracil
60
Blood Specimen Collection
58
Bevacizumab
58
fludarabine
54
Rituximab
54
Etoposide
53
Oxaliplatin
52
Surveys and Questionnaires
49
Lenalidomide
49
Prednisone
47
Standard of Care
45
Magnetic Resonance Spectroscopy
45
Cetuximab
44
Capecitabine
44
lenvatinib
43
Radiosurgery
43
durvalumab
42
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Completed
×
ipatasertib
×
1 year
×
Clear all
NCT04253561
2026-03-16
IPATHER
SOLTI Breast Cancer Research Group
Phase 1
Completed
17 enrolled
NCT03498521
2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2
Completed
529 enrolled
16 charts
NCT03280563
2025-11-10
MORPHEUS HR+BC
Hoffmann-La Roche
Phase 1/2
Completed
144 enrolled
25 charts